Baxter International, DVC present Stage III clinical efficacy data for PREFLUCEL Baxter International Inc. , together with DynPort Vaccine Organization LLC , a CSC Company , presented today Phase III research data measuring the scientific efficacy for PREFLUCEL, a trivalent seasonal influenza applicant vaccine dmae . The info were offered at the International Congress on Infectious Disease in Miami, Florida. The scholarly research was conducted through the 2008/2009 influenza season in the usa in a lot more than 7,000 healthy clinical trial individuals ages 18 to 49. Ehrlich, M.D., vice president of Global Research and Advancement for Baxter’s BioScience business.
It’s estimated that 20,000 folks are coping with hemophilia in the U.S. Today. Bayer Health care is focused on delivering science for an improved lifestyle by advancing a portfolio of remedies. Hematology at Bayer Health care includes numerous substances in a variety of stages of advancement for hemophilia, sickle cell anemia, and other bloodstream and bleeding disorders. Collectively, these substances reflect the company's commitment to advancement and research, prioritizing particular targets for intervention with the potential to boost just how that rare bloodstream and bleeding disorders are treated.. Bayer announces FDA acceptance of BAY 81-8973 BLA for treatment of hemophilia A Bayer Health care today announced that the U.S.